These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10550412)

  • 21. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Badia X; Russo P; Attanasio E
    Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
    Wilhelmsen L; Welin L; Odén A; Björnberg A
    Eur J Health Econ; 2010 Apr; 11(2):177-84. PubMed ID: 19495819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 26. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
    Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
    Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
    Zou Y; Hu D; Yang X; Xu Z; Cui L; Liu X; Wei Y; Gao M
    Chin Med J (Engl); 2003 Jun; 116(6):853-6. PubMed ID: 12877794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
    Grover SA; Coupal L; Zowall H; Dorais M
    Circulation; 2000 Aug; 102(7):722-7. PubMed ID: 10942738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.
    Janzon M; Levin LA; Swahn E
    Eur Heart J; 2002 Jan; 23(1):31-40. PubMed ID: 11741360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
    Pedersen TR; Kjekshus J; Pyörälä K; Olsson AG; Cook TJ; Musliner TA; Tobert JA; Haghfelt T
    Am J Cardiol; 1998 Feb; 81(3):333-5. PubMed ID: 9468077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins.
    Pearson TA
    Am J Cardiol; 1998 Nov; 82(10A):28S-30S. PubMed ID: 9860353
    [No Abstract]   [Full Text] [Related]  

  • 37. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age.
    Massing MW; Sueta CA; Chowdhury M; Biggs DP; Simpson RJ
    Am J Cardiol; 2001 Mar; 87(5):646-9, A10. PubMed ID: 11230856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of coronary heart disease: incremental cost effectiveness raises issues.
    D'Avanzo WC
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962886
    [No Abstract]   [Full Text] [Related]  

  • 39. Controversies in dyslipidaemia management.
    Stock J
    Atherosclerosis; 2012 Apr; 221(2):321-4. PubMed ID: 22305261
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing the benefits of lipid-lowering therapy.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):2M-4M. PubMed ID: 9766341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.